Our inventions have no revenue behind them. Can they be valued at all?

Yes, from the market volume. The method that starts from company revenue needs the owner's revenue and gives zero without it, on purpose. The combined value therefore rests on the market volume, and the report states which of the two methods it used.

Can a university be the originator in the partner search?

Yes. The originating owner is any owner with valued families still in term, whatever the assignee type. One limit applies: product-family research skips academic owners, so the candidate evidence rests on patents, categories and geography instead of on your products.

We want to prioritise before filing, not after.

The valuation works on filed families. For deciding what to file next, the field itself is the guide: the lifecycle phase, the academic and industrial filing curves, and who already files in the sub-category you are looking at.

What does the industry partner get to see?

The same derivation you see, with method, assumptions, weights and sources, and the PDF report with the technology transfer lifecycle spread. A figure the other side can recompute turns the conversation into a negotiation.

You've researched something new. Who brings it to market with you?

mar:val shows what each of your inventions is worth in its market and what a partner would need to earn with it. It names the companies best placed to take it to market, down to the people in them.

Request a demo

- Your invention · Optical aperture
Relief from royalty
- Value in its market · $2.4M
Required revenue
- Partner must earn · $11.8M
Partners ranked
- Medtronix · 92%
- Biosense AG · 78%
- Institut Helvet · Academia
Decision-makers
- Head of R&D · By name

Example · invention to partner

One invention, step by step

01Your invention

Which of your inventions goes first?

mar:val analyses your institute like any company in the field, whatever its size. Each invention gets its value in its market, the sales a partner would need, its remaining term and where it is in force.

Research in this field

Research institutions: 37
Inventions per institution: 4.2
Survival rate: 61%

Inventions: 6
Portfolio value: $6.2M
Licence fee equivalent / yr: $1.2M

Your institute's inventions, ranked by value
Invention	Value	Partner must sell / yr	Term
1Self-calibrating optical aperture13 yrs · EP US CN JP KR	$2.4M	$11.8M	13 yrs
2Ion-selective membrane stack17 yrs · EP US	$1.7M	$7.7M	17 yrs
3In-operation sensor calibration6 yrs · EP US CN JP	$1.1M	$8.1M	6 yrs
4Low-temperature catalyst carrier18 yrs · EP	$0.6M	$2.7M	18 yrs
5Anti-fouling surface coating9 yrs · DE	$0.3M	$1.7M	9 yrs
6Modular test fixture3 yrs · DE EP	$0.1M	$1.2M	3 yrs

Example · Technologies · Company portfolio details

02Value in its market

What is it worth without a revenue line?

An institute sells no product, so the method that starts from company revenue gives zero, on purpose. The method that starts from market volume prices the invention at the licence fee its users would otherwise pay. The report names the method the value rests on.

From company revenue: $0; No revenue line
From market volume: $2.4M
Value: $2.4M; Rests on market volume

Royalty rate: 3.5%
WACC: 8.4%
Remaining term: 13 yrs
In force: EP US CN JP KR

Example · Technologies · Valuation approach

03Partner must earn

What would a partner have to sell?

At the field's royalty rate of 3.5%, $2.4M is a licence fee of $0.41M a year for the 13 years left. A partner pays that out of $11.8M a year in sales with your technology. Each fee counts for less the later it falls, and only while the right is likely to be in force.

Licensing in this field

Active families that changed owner: 18%
Families filed jointly: 12%

Sales with your technology / yr: $11.8M
Royalty rate: 3.5%
Licence fee / yr: $0.41M

13 years, worth today$2.4M

Example · Technologies · Valuation approach

04Partners ranked

Who is best placed to take it to market?

Matchmaking ranks the companies with a reason to bring your invention to market, each with the evidence behind its rank. Filter to industry, or to research institutions for a joint development.

1Medtronix: 92
2Biosense AG: 78
3Institut HelvetResearch: 71
4Coredex: 64
5Novalis GmbH: 58

Evidence · Medtronix

Patent pairs
Semantic
Category

Your institute: Partner & out-license
Medtronix: Scale & protect
Biosense AG: Scale & protect
Institut Helvet: Partner & out-license
Coredex: Innovate & in-license
Novalis GmbH: Innovate & in-license

Example · Matchmaking · Strength matrix

05Decision-makers

Whom do you talk to there?

mar:val names the people who decide on technology and R&D strategy at each candidate and ranks them by influence, each with role, source and a direct LinkedIn search.

At Medtronix

1Head of R&D, optical systemsCompany websiteLinkedIn search
2Chief technology officerAnnual reportLinkedIn search
3Head of business developmentPress releaseLinkedIn search
4Head of licensingCompany websiteLinkedIn search

Example · Matchmaking · Key personnel

The report

One spread your board can read.

The PDF report has a technology transfer spread with nine figures computed from your field. Here are four of them for this example.

R&D per invention: $1.9M
Years to peak sales: 7
Partnership rate: 12%
Annual royalty equivalent: $1.2M

And five more

Request a demo

What you are probably asking now

Yes, from the market volume. The method that starts from company revenue needs the owner's revenue and gives zero without it, on purpose. The combined value therefore rests on the market volume, and the report states which of the two methods it used.

The other five situations

Demo request

Know what your technology is worth.

In the demo we show you a real report from your technology field. 30 minutes, no obligation.

Questions first? contact@marlean.com